99 results
S-8 POS
EX-5.1
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees (post-effective amendment)
5:12pm
of the failure to vest or is reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price
S-8 POS
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees (post-effective amendment)
5:12pm
, is forfeited because of the failure to vest or is reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise
S-8
EX-4.3
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your … provide Continuous Service (the “Service Recipient”) with respect to any income tax, social insurance, payroll tax, fringe benefits tax, payment
S-8
EX-4.6
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
, establishment of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax … the date the Plan is adopted by the Board, or (iii) as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear
S-8
EX-4.2
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
or purchase price of an Award; or (4) the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation … that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3) any shares that are reacquired by the Company to satisfy a tax
S-8
EX-4.4
451h3h
22 May 24
Registration of securities for employees
4:33pm
S-8
EX-4.5
wdk6w s6hfn4
22 May 24
Registration of securities for employees
4:33pm
8-K
EX-99.1
eh2q0at h87zvta68u
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
424B5
uq53hcgr sf
1 Mar 24
Prospectus supplement for primary offering
4:13pm
8-K
EX-1.1
pr0xkrg
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
424B5
dkdf3swhycpi1xos05
27 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
pp3tq1prm
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
7kze2irx zj
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
S-3ASR
ta2qo2ecb2sy4k
26 Jul 23
Automatic shelf registration
5:26pm